TheraRadar
Clinical-Stage Companies / Adamas

Adamas

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 7/18/2018

10
Total Trials
8
Phase 3
3
Phase 2
0
Recruiting
144
Score

Pipeline by Phase

Phase 3
8
Phase 2
3
Phase 1

Therapeutic Focus

Parkinson's Disease Dyskinesia Levodopa Induced Dyskinesia (LID) Multiple Sclerosis Walking Impairment

Clinical Trials (10)

NCT02153645 Phase 3 TERMINATED

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

Started: 8/18/2014

NCT02153632 Phase 3 TERMINATED

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

Started: 7/30/2014

NCT03567057 Phase 3 COMPLETED

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Started: 7/18/2018

NCT03436199 Phase 3 COMPLETED

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Started: 3/29/2018

NCT02202551 Phase 3 COMPLETED

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Started: 7/1/2014

NCT02136914 Phase 3 COMPLETED

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Started: 5/1/2014

NCT02274766 Phase 3 COMPLETED

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

Started: 10/1/2014

NCT01397422 Phase 2 COMPLETED

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Started: 7/1/2011

NCT02471222 Phase 2 COMPLETED

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Started: 5/1/2015

NCT00979251 Phase 2 COMPLETED

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

Started: 9/1/2009

Drug Candidates

240mg Amantadine HCl ER tablets Placebo tablets 320mg Amantadine HCl ER tablets amantadine HCl ER Placebo ADS-5102, 274 mg ADS-5102, 137 mg ADS-5102 ADS-5102 (extended release amantadine HCl) Oseltamivir Phosphate
Activity Status: Inactive
Last Trial Started: 7/18/2018
Last Trial Ended: 4/18/2021
Trials (12 months): 0
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.